XTX Topco Ltd Makes New Investment in Inogen, Inc (NASDAQ:INGN)

XTX Topco Ltd acquired a new stake in shares of Inogen, Inc (NASDAQ:INGN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,230 shares of the medical technology company's stock, valued at approximately $237,000. XTX Topco Ltd owned about 0.12% of Inogen at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. GSA Capital Partners LLP increased its holdings in Inogen by 36.3% during the 1st quarter. GSA Capital Partners LLP now owns 76,574 shares of the medical technology company's stock valued at $546,000 after purchasing an additional 20,411 shares during the period. Inspire Advisors LLC bought a new position in Inogen in the 1st quarter worth $314,000. Royce & Associates LP lifted its position in shares of Inogen by 42.8% in the 1st quarter. Royce & Associates LP now owns 444,457 shares of the medical technology company's stock worth $3,169,000 after purchasing an additional 133,258 shares during the period. CWM LLC boosted its stake in shares of Inogen by 71.7% during the 1st quarter. CWM LLC now owns 14,647 shares of the medical technology company's stock valued at $104,000 after purchasing an additional 6,118 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of Inogen during the first quarter valued at about $99,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on INGN shares. B. Riley started coverage on shares of Inogen in a report on Monday, June 16th. They issued a "buy" rating and a $14.00 price objective for the company. Needham & Company LLC upgraded Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus reduced their price target on Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th.

Inogen Stock Down 2.7%

Shares of NASDAQ INGN traded down $0.21 on Friday, reaching $7.46. 182,241 shares of the company's stock traded hands, compared to its average volume of 284,956. The business's 50 day simple moving average is $6.80 and its two-hundred day simple moving average is $7.43. Inogen, Inc has a 12 month low of $5.70 and a 12 month high of $13.33. The company has a market cap of $201.72 million, a price-to-earnings ratio of -7.04 and a beta of 1.72.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%. The company had revenue of $92.28 million during the quarter, compared to analyst estimates of $90.40 million. Analysts forecast that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.